Literature DB >> 16508754

Sepsis in the ICU: who needs progress?

Jean-Louis Vincent.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16508754     DOI： 10.1007/s00134-006-0089-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

2.  The patents-based pharmaceutical development process: rationale, problems, and potential reforms.

Authors:  John H Barton; Ezekiel J Emanuel
Journal:  JAMA       Date:  2005-10-26       Impact factor: 56.272

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Authors:  Jean-Louis Vincent; Gordon R Bernard; Richard Beale; Christopher Doig; Christian Putensen; Jean-Francois Dhainaut; Antonio Artigas; Roberto Fumagalli; William Macias; Theressa Wright; Kar Wong; David P Sundin; Mary Ann Turlo; Jonathan Janes
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

Review 5.  New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

Authors:  William L Macias; S Betty Yan; Mark D Williams; Suzane L Um; George E Sandusky; Darryl W Ballard; Jean-Michel S Planquois
Journal:  Crit Care       Date:  2005-08-25       Impact factor: 9.097
  5 in total
  2 in total

1.  The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia.

Authors:  Jeppe Sylvest Nielsen; Anders Larsson; Thomas Rix; Rasmus Nyboe; Jakob Gjedsted; Jan Krog; Thomas Ledet; Else Tønnesen
Journal:  Intensive Care Med       Date:  2007-04-25       Impact factor: 17.440

2.  Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

Authors:  Vania Costa; James M Brophy
Journal:  BMC Anesthesiol       Date:  2007-06-25       Impact factor: 2.217
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.